Pirprofen and aspirin in the treatment of rheumatoid arthritis

Publisher Website
Google Scholar
Abstract
Pirprofen (800 mg/day) or aspirin (3,600 mg/day) was administered in double‐blind fashion for up to one yr to 40 adult outpatients with rheumatoid arthritis, after a short, single‐blind placebo period. There were no statistically significant differences in efficacy between pirprofen and aspirin, as evidenced by patient opinion, observer opinion, grip strength, walking time, number of tender joints, number of swollen joints, or erythrocyte sedimentation rate. Clinically significant pain of gastrointestinal origin occurred in an equal number of patients from each group. Audiologic evaluation revealed 3 pirprofen‐treated patients and 5 aspirin‐treated patients in whom a sensorineural hearing loss progressed during therapy and required either discontinuation or reduction of drug dosage. Ophthalmologic evaluation disclosed a high prevalence of lesions, the most common being decreased visual acuity and cataracts not explained by previous antiarthritic therapy. The high prevalence of audiologic and ophthalmologic pathology reported in the literature in patients with rheumatoid arthritis makes it difficult to establish in our study whether pirprofen or aspirin affected these organ systems.

This publication has 2 references indexed in Scilit: